Form 4: C4 Therapeutics Director Malcolm Salter Acquires Stock Options
SEC Form 4 Filing
Director Malcolm Salter acquired stock options in C4 Therapeutics, Inc. on June 20, 2024.
Summary
- On June 20, 2024, Malcolm Salter, a director of C4 Therapeutics, Inc., acquired 32,500 stock options with an exercise price of $4.05.
- These options vest fully on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service on the Board.
- Following the transaction, Salter directly owns 32,500 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be seen as a positive sign of alignment with company goals, but doesn't provide enough information to strongly influence sentiment.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The acquisition of stock options by a director can positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of the transaction: Malcolm Salter acquired stock options. |
| 06/20/2025 | Earliest vesting date for the stock options, contingent on continued service on the board. |
| 06/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.